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Introduction 
The diagnostic marker for HCV infection is now 
well established, though it is expected that the 
assay method, sensitivity and specificity will fur- 
ther improve in the near future. Reports on 
clinical and seroepidemiology studies of HCV are 
being published from different parts of the world, 
mostly from the developed countries 1-3. The glob- 
al status of HCV hepatitis will emerge when 
these studies are extended to all the regions of the 
world, particularly to include the tropical and 
developing countries. Fulminant hepatitis failure 
(FHF) and Subacute hepatic failure (SAHF) are 
common manifestations of hepatitis in India. We 
report here HCV as the major cause of the severe 
form of liver disease in India, which includes ful- 
minant hepatic failure (FHF), subacute hepatic 
failure (SAHF) and chronic active hepatitis 
(CAH). 
were tested using EIA-kits from Abbott (USA). 
HBsAg was detected by a modified micro-ELISA 
technique6'7; IgM anti-HAV and IgM anti-HBc 
were investigated in sera samples using HAVAB- 
M and CORZYME-M kits respectively. Anti- 
HCV antibody was tested in sera samples using 
HCV-EIA kit from Ortho Diagnostic. 
The diagnosis of hepatitis A and B infections 
were confirmed by the presence of IgM anti-HAV 
and IgM anti-HBc respectively in sera samples. 
Sera negative for both these markers were diag- 
nosed as due to NANB infections. Further sera 
positive for HBsAg but negative for IgM anti- 
bodies were labelled as HBV carriers associated 
with other hepatitis viral infections. The presence 
of anti-HCV antibody in HBsAg-positive but IgM 
anti-HBC negatives sera indicated superinfection 
of HCV in HBV carrier, where as the presence of 
both anti-HCV and IgM anti HBc together estab- 
lished coinfection of HCV with HBV infection. 
Patients and Methods 
A total number of 167 patients which included 
81 cases of fulminant hepatitis, 53 of subacute 
hepatic failure and 33 of chronic active hepatitis 
were investigated for anti-HCV antibodies and 
the markers of hepatitis A and B infections. The 
diagnosis of fulminant hepatitis, subactue hepatic 
failure and chronic active hepatitis were estab- 
lished on accepted clinical, biochemical and his- 
tological criteria 4'5. 
The serological markers for hepatitis A and B 
Results 
Table 1 presents the anti-HCV positivity rate in 
FHF, SAHF and CAH. The results show that 
HCV antibodies were present in 43%, 47% and 
42% respectively. Table 2 shows that HCV was 
the exclusive tiological agent for 20.9% cases of 
FHF, 18.7% of SAHF and 15.2% of CAH re- 
spectively. Further, HCV infection has made 
an additional contribution to the severe .form of 
liver diseases either as superinfection or coin- 
fection with HBV virus. These data have been an- 
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Table 1 Anti-HCV positivity in FHF, SAHF and CAH 
Group No. tested No. positive % positive 
FHF 81 35 43.2 
SAHF 53 25 47.2 
CAH 33 16 42.1 
Total 167 79 44.9 
alyzed in Tables 3 and 4. Single HCV infection as 
the cause of severe liver disease was recorded 
in 43.6%, 41.7% and 50% respectively in FHF, 
SAHF and CAH. HCV superinfection i  HBsAg 
carriers was recorded in 54% of FHF, 60% of 
SAHF and 42% of CAH cases (Table 4). Further, 
coinfection of HCV and HBV was recorded in 
Table 2 HCV as single etiological agent in FHF, SAHF and CAH 
Disease No. anti-HCV+ %HCV infection 
No. tested 
group (exclusively) (single agent) 
FHF 81 17 20.9 
SAHF 53 10 18.7 
CAH 33 5 15.2 
27.8% of FHF, 42.9% of SAHF and 75% of CAH 
respectively (Table 4). 
Table 5 summarizes the etiological spectrum 
due to hepatitis viruses in three severe types of 
clinical hepatitis in our patients. It may be noted 
that hepatitis A infection has not been recorded in 
any patient in this series. Hepatitis C as a single 
infection or superinfection/coinfection withhepa- 
Table 3 Relative contribution of HCV infection to NANB hepatitis group of patients 
Group Total 
NANB infection 
No. Percentage 
Anti-HCV positivity in NANB group of cases 
No. +VE %+VE 
FHF 81 39 48.2 39 17 43.6 
SAHF 53 24 45.3 24 10 41.7 
CAH 33 10 30.3 10 5 50.0 
Table 4 HCV coinfection and superinfection with HBV 
Group 
HCV superinfection 
No.* anti-HCV+ %+VE 
HCV coinfection 
No.** anti-HCV+ %+VE 
FHF 24 13 54.2 18 5 27.8 
SAHF 15 9 60.0 14 6 42.9 
CAH 19 8 42.1 4 3 75.0 
*: All sera positive for HBsAg, **: All sera positive for IgM anti-HBc 
Table 5 Etiological spectrum of FHF, SAHF and CAH patients 
Type of hepatitis 
FHF (n=81) SAHF (n=53) CAH (n=33) 
+VE %+VE +VE %+VE +VE %+VE 
Hepatitis A 0 0 0 0 0 0 
Hepatitis B 18 22.2 14 26.4 4 12.1 
(i) Single infectin 17 20.9 10 18.8 5 15.2 
(ii) Superinfection in HBV carrier 13 16.1 9 16.9 8 24.2 
(iii) HBV and HCV coinfectin 5 6.2 6 11.3 3 9.1 
(iv) Hepatitis-NANBNC 
(i) Single infection 22 27.2 14 26.4 5 15.2 
(i) Superinfection in HBV carrier 11 45.8 6 40.0 11 57.8 
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titis B has been recorded in 43.2% of FHF, 47% 
of SAHF and 48% of CAH of patients. A group of 
patients comprising 27.2% of FHF, 26.4% of 
SAHF and 15.2% of CAH patients did not have 
positive serology for HAV, HBV or HCV infec- 
tion. The patients in this group may have been 
infected due to HEV or a second type of a yet 
unidentified HCV virus (referred to by some as 
HFV or some yet unknown hepatitis virus). 
Discussion 
In 19857, we reported that NANB hepatitis is a 
public health problem in India. The confusion 
about the NANB hepatitis group has significantly 
cleared after the discovery of serological test 
for HCV s and isolation of the HEV virus 9. It is 
now well established that what was labelled as 
NANB hepatitis includes the following diseases: 
(a) hepatitis C virus infection, (b) hepatitis E virus 
infection, and (c) an unkown hepatitis infection 
which may be a variant of HCV or yet another 
hepatitis virus which in future may be labelled 
as hepatitis F infection. 
Recent studies, particularly from the USA a~ 
Japan 11 and Europe 12 have described the epidemi- 
ology and clinical spectrum of hepatitis C virus 
infection. It has been reported that fulminant 
cases are rare in prospectively followed patients 
with transfusion-associated NANB hepatitis 
which now is believed to be primarily due to HCV 
infection. However, when patients presenting as 
fulminant hepatitis were categorised by etiology, 
NANB has been attributed as the primary 
cause ~3. The earlier eports 7 from our department 
indicated the etiological spectrum of 130 fulmi- 
nant hepatitis cases recording hepatitis A, B, 
NANB an~d associated NANB in HBsAg carriers 
infections in 15%, 27%, 53% and 9% cases re- 
spectively. The serological tests for HCV were 
not developed when this study was carried out. 
The present report in 81 cases of FHF reveals a 
major etiological role of HCV. In 21% patients 
it was noted as exclusive infection, 16% had 
superinfection f HCV in HBV carriers and 6.2% 
had coinfection of HCV and HBV. Thus overall 
43% of all FHF cases had HCV infection. We do 
not know the exact etiology in reference to type of 
hepatitis virus in 27% of patients where markers 
of HAV, HBV and HCV were all negative. These 
patients may include cases of HEV infection, a 
second type of HCV virus or some other unkown 
hepatitis virus. None of them had a history of 
injection or consumption of drugs known to be 
associated with fulminant hepatic failure. 
Subacute hepatic failure has been described in 
a large series of patients of acute viral hepatitis 
with bridging necrosis from our department. I  is a 
distinct entity 14, different from FHF and CAH, It 
has a high mortality in the same range as FHF. 
HCV as a single or superinfection in HBV carriers 
or coinfection with HBV has been recorded in 
47% of patients in this group. Earlier, our labo- 
ratory reported NANB hepatitis as the etiology 
of SAHF in 37% of the patients 7. It was noted in 
the present series that 26% of patients did not 
have seropositivity for hepatitis A, B, or C. The 
infection in this group may be due to hepatitis E
or a second type of hepatitis C or some unknown 
hepatitis virus. 
The strongest association of HCV has been 
reported with chronic active hepatitis in Western 
literature and from Japan 1-3. Prospective studies 
have shown that nearly 50% of the post-transfu- 
sion and community-based acute sporadic hepa- 
titis due to HCV progress to chronic hepatitis. It 
is reported that in community-acquired chronic 
active hepatitis up to 80% cases are due to HCV 
infection is. The present data of our department 
reveals that 48.5% cases of chronic active hepa- 
titis (community-acquired) had HCV infection 
which included exclusive infection due to HCV 
as well as super-and coinfection with HBV. As in 
the case of FHF and SAHF a group of patients 
less in number than those with the previous 
two diseases was serologically negative for hepa- 
titis A, B or C markers. This group may have 
hepatitis E infection or a second type of HCV 
disease. 
In conclusion, the data of the present study 
establish that HCV is an important etiological 
agent in nearly half of the cases in the three severe 
forms of community-acquired hepatitis namely 
FHF, SAHF, and CAH in India. 
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Summary 
The present study describes the status of hepatitis 
C virus infection in 167 patients with severe forms 
of liver diseases in India. The anti-HCV positivity 
rate was recorded as 43%, 47% and 42% in pa- 
tients with FHF, SAHF and CAH respectively. 
HBV and HCV coinfection was recorded in 28% 
of FHF, 43% of SAHF and 75% of the CAH 
cases. Superinfection of HCV in HBsAg carriers 
was recorded in 54% cases of FHF, 60% of SAHF 
and 42% of the CAH. None of these 167 patients 
was positive of HAV-IgM. Further, 27.7% of 
FHF, 26.4% of SAHF and 15.2% of CAH cases 
were neither HBV nor HCV markers positive. 
These can be labelled as non-A, non-B and non- 
C infections. 
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